LumiThera, Inc. is a medical device company focused on treating patients affected by dry age-related macular degeneration. The company’s expertise is in the application of Photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The company is commercializing the CE Marked Valeda™ Light Delivery System, an ophthalmic office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Valeda is the first approved treatment for Dry AMD using Photobiomodulation.
MacuLogix, Inc. equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx®, MacuLogix is working to eliminate preventable blindness caused by AMD, a disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx dark adaptometer, MacuLogix enables eye care professionals to detect, monitor and treat AMD at least three years before it can be seen clinically.